AXA acquired a new position in shares of BioTime, Inc. (NYSEAMERICAN:BTX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,298,681 shares of the biotechnology company’s stock, valued at approximately $4,942,000. AXA owned about 1.81% of BioTime as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. Citadel Advisors LLC raised its holdings in BioTime by 90.8% during the fourth quarter. Citadel Advisors LLC now owns 148,814 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 70,827 shares during the last quarter. Artal Group S.A. raised its holdings in shares of BioTime by 21.5% in the fourth quarter. Artal Group S.A. now owns 1,557,050 shares of the biotechnology company’s stock worth $3,348,000 after acquiring an additional 275,000 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of BioTime by 124.1% in the third quarter. GSA Capital Partners LLP now owns 174,816 shares of the biotechnology company’s stock worth $496,000 after acquiring an additional 96,816 shares during the last quarter. Family Management Corp raised its holdings in shares of BioTime by 29.9% in the third quarter. Family Management Corp now owns 182,350 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 41,979 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of BioTime by 10.3% in the second quarter. State Street Corp now owns 1,345,379 shares of the biotechnology company’s stock worth $4,238,000 after acquiring an additional 125,833 shares during the last quarter.
A number of equities analysts have recently weighed in on the company. Lake Street Capital assumed coverage on BioTime in a report on Friday, February 2nd. They issued a “buy” rating and a $8.00 price target for the company. Zacks Investment Research cut BioTime from a “hold” rating to a “strong sell” rating in a report on Thursday, March 22nd. Three analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. BioTime presently has a consensus rating of “Hold” and an average price target of $5.75.
Shares of NYSEAMERICAN BTX traded down $0.08 during trading on Friday, reaching $2.33. The company had a trading volume of 435,683 shares, compared to its average volume of 529,918. BioTime, Inc. has a twelve month low of $2.10 and a twelve month high of $3.50.
BioTime (NYSEAMERICAN:BTX) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $2.38 million. BioTime had a net margin of 828.55% and a return on equity of 30.68%.
WARNING: “Axa Takes Position in BioTime, Inc. (NYSEAMERICAN:BTX)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/axa-takes-position-in-biotime-inc-btx.html.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.